$MIRM
Mirum Pharmaceuticals, Inc.

2022 Q4 Form 10-Q Financial Statement

#000095017022023519 Filed on November 09, 2022

View on sec.gov

Income Statement

Concept 2022 Q4 2022 Q3 2021 Q3
Revenue $27.91M $18.78M $5.000M
YoY Change 789.29% 275.6%
Cost Of Revenue $4.494M $2.932M
YoY Change 136.15%
Gross Profit $23.41M $15.85M
YoY Change 1795.71%
Gross Profit Margin 83.9% 84.39%
Selling, General & Admin $26.47M $22.51M $17.35M
YoY Change 39.05% 29.74% 202.84%
% of Gross Profit 113.05% 142.06%
Research & Development $31.11M $26.22M $30.47M
YoY Change 11.99% -13.96% 90.63%
% of Gross Profit 132.86% 165.43%
Depreciation & Amortization $1.201M $1.096M $84.00K
YoY Change 251.17% 1204.76% 5.0%
% of Gross Profit 5.13% 6.92%
Operating Expenses $57.57M $51.66M $47.82M
YoY Change 22.99% 8.03% 120.22%
Operating Profit -$34.16M -$32.88M -$42.82M
YoY Change -25.04% -23.22% 97.2%
Interest Expense -$1.542M -$2.619M -$4.240M
YoY Change -68.21% -38.23% -1866.67%
% of Operating Profit
Other Income/Expense, Net -$588.0K -$192.0K -$35.00K
YoY Change 3358.82% 448.57% 16.67%
Pretax Income -$36.29M -$35.69M -$47.10M
YoY Change -163.05% -24.22% 118.97%
Income Tax $140.0K $13.00K $9.000K
% Of Pretax Income
Net Earnings -$36.43M -$35.71M -$47.11M
YoY Change -163.31% -24.2% 119.05%
Net Earnings / Revenue -130.55% -190.13% -942.16%
Basic Earnings Per Share -$1.02 -$1.55
Diluted Earnings Per Share -$0.99 -$1.02 -$1.551M
COMMON SHARES
Basic Shares Outstanding 36.87M 32.75M 30.52M
Diluted Shares Outstanding 34.93M 30.37M

Balance Sheet

Concept 2022 Q4 2022 Q3 2021 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $151.7M $185.3M $190.0M
YoY Change -3.08% -2.47% 42.08%
Cash & Equivalents $28.00M $35.76M $55.84M
Short-Term Investments $123.7M $149.6M $134.2M
Other Short-Term Assets $8.947M $6.929M $6.371M
YoY Change 69.74% 8.76% 44.8%
Inventory $5.565M $6.943M
Prepaid Expenses
Receivables $23.99M $16.34M $400.0K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $190.2M $215.6M $196.8M
YoY Change 14.19% 9.53% 42.41%
LONG-TERM ASSETS
Property, Plant & Equipment $914.0K $795.0K $1.060M
YoY Change -6.83% -25.0% -68.82%
Goodwill
YoY Change
Intangibles $58.95M $45.03M $19.00M
YoY Change 214.59% 137.01%
Long-Term Investments $0.00 $0.00 $15.00M
YoY Change -100.0% -100.0%
Other Assets $1.382M $1.710M $1.641M
YoY Change -22.62% 4.2% 447.0%
Total Long-Term Assets $162.7M $148.8M $38.36M
YoY Change 27.04% 287.86% 936.81%
TOTAL ASSETS
Total Short-Term Assets $190.2M $215.6M $196.8M
Total Long-Term Assets $162.7M $148.8M $38.36M
Total Assets $352.9M $364.3M $235.2M
YoY Change 19.77% 54.93% 65.73%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $8.690M $10.55M $5.003M
YoY Change -5.19% 110.83% -3.79%
Accrued Expenses $54.02M $38.31M $43.85M
YoY Change 75.82% -12.63% 222.4%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $64.73M $51.40M $50.39M
YoY Change 51.96% 2.01% 168.02%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $4.532M $4.324M $19.00K
YoY Change 26558.82% 22657.89% -99.32%
Total Long-Term Liabilities $4.532M $4.324M $19.00K
YoY Change 26558.82% 22657.89% -99.32%
TOTAL LIABILITIES
Total Short-Term Liabilities $64.73M $51.40M $50.39M
Total Long-Term Liabilities $4.532M $4.324M $19.00K
Total Liabilities $210.9M $195.1M $178.8M
YoY Change 20.88% 9.11% 727.64%
SHAREHOLDERS EQUITY
Retained Earnings -$392.8M -$356.4M -$314.7M
YoY Change 52.75% 13.25%
Common Stock $535.1M $526.1M $371.1M
YoY Change 41.78% 41.77%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $142.0M $169.3M $56.40M
YoY Change
Total Liabilities & Shareholders Equity $352.9M $364.3M $235.2M
YoY Change 19.77% 54.93% 65.73%

Cashflow Statement

Concept 2022 Q4 2022 Q3 2021 Q3
OPERATING ACTIVITIES
Net Income -$36.43M -$35.71M -$47.11M
YoY Change -163.31% -24.2% 119.05%
Depreciation, Depletion And Amortization $1.201M $1.096M $84.00K
YoY Change 251.17% 1204.76% 5.0%
Cash From Operating Activities -$34.27M -$26.03M -$34.20M
YoY Change 3.39% -23.91% 96.0%
INVESTING ACTIVITIES
Capital Expenditures $242.0K -$19.00K -$18.00K
YoY Change -101.27% 5.56% -64.0%
Acquisitions
YoY Change
Other Investing Activities $27.00M -$79.51M -$2.219M
YoY Change -78.74% 3483.15% -88.24%
Cash From Investing Activities $26.76M -$79.53M -$2.237M
YoY Change -75.23% 3455.16% -88.17%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities -329.0K 86.07M 345.0K
YoY Change -153.5% 24846.67% -83.57%
NET CHANGE
Cash From Operating Activities -34.27M -26.03M -34.20M
Cash From Investing Activities 26.76M -79.53M -2.237M
Cash From Financing Activities -329.0K 86.07M 345.0K
Net Change In Cash -7.841M -19.49M -36.09M
YoY Change -110.39% -46.01% 5.35%
FREE CASH FLOW
Cash From Operating Activities -$34.27M -$26.03M -$34.20M
Capital Expenditures $242.0K -$19.00K -$18.00K
Free Cash Flow -$34.51M -$26.01M -$34.18M
YoY Change 144.0% -23.92% 96.46%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2021Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Entity Central Index Key
EntityCentralIndexKey
0001759425
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
CY2022Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2022-09-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2022
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-38981
dei Entity Registrant Name
EntityRegistrantName
Mirum Pharmaceuticals, Inc.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
83-1281555
dei Entity Address Address Line1
EntityAddressAddressLine1
950 Tower Lane, Suite 1050,
dei Entity Address City Or Town
EntityAddressCityOrTown
Foster City
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94404
dei City Area Code
CityAreaCode
650
dei Local Phone Number
LocalPhoneNumber
667-4085
dei Security12b Title
Security12bTitle
Common stock, par value $0.0001 per share
dei Trading Symbol
TradingSymbol
MIRM
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
dei Entity Ex Transition Period
EntityExTransitionPeriod
true
dei Entity Shell Company
EntityShellCompany
false
CY2022Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
36870380
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
35759000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
31340000
CY2022Q3 us-gaap Short Term Investments
ShortTermInvestments
149588000
CY2021Q4 us-gaap Short Term Investments
ShortTermInvestments
125201000
CY2022Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
16337000
CY2021Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
3267000
CY2022Q3 us-gaap Inventory Net
InventoryNet
6943000
CY2021Q4 us-gaap Inventory Net
InventoryNet
1513000
CY2022Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
6929000
CY2021Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
5271000
CY2022Q3 us-gaap Assets Current
AssetsCurrent
215556000
CY2021Q4 us-gaap Assets Current
AssetsCurrent
166592000
CY2022Q3 us-gaap Restricted Cash Equivalents
RestrictedCashEquivalents
100000000
CY2021Q4 us-gaap Restricted Cash Equivalents
RestrictedCashEquivalents
100000000
CY2022Q3 us-gaap Long Term Investments
LongTermInvestments
0
CY2021Q4 us-gaap Long Term Investments
LongTermInvestments
4983000
CY2022Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
795000
CY2021Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
981000
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1254000
CY2021Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1569000
CY2022Q3 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
45032000
CY2021Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
18740000
CY2022Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1710000
CY2021Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1786000
CY2022Q3 us-gaap Assets
Assets
364347000
CY2021Q4 us-gaap Assets
Assets
294651000
CY2022Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
10548000
CY2021Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
9166000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
38311000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
30723000
CY2022Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
775000
CY2021Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
711000
CY2022Q3 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
1764000
CY2021Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
1996000
CY2022Q3 us-gaap Liabilities Current
LiabilitiesCurrent
51398000
CY2021Q4 us-gaap Liabilities Current
LiabilitiesCurrent
42596000
CY2022Q3 mirm Revenue Interest Liability Noncurrent
RevenueInterestLiabilityNoncurrent
138017000
CY2021Q4 mirm Revenue Interest Liability Noncurrent
RevenueInterestLiabilityNoncurrent
129923000
CY2022Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1311000
CY2021Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1903000
CY2022Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
4324000
CY2021Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
17000
CY2022Q3 us-gaap Liabilities
Liabilities
195050000
CY2021Q4 us-gaap Liabilities
Liabilities
174439000
CY2022Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2021Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2022Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2021Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2022Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2021Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2021Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2022Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2021Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2021Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2022Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
36836024
CY2022Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
36813754
CY2022Q3 mirm Common Stock Shares Outstanding Subject To Repurchase
CommonStockSharesOutstandingSubjectToRepurchase
22270
CY2021Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
30705060
CY2021Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
30582596
CY2021Q4 mirm Common Stock Shares Outstanding Subject To Repurchase
CommonStockSharesOutstandingSubjectToRepurchase
122464
CY2022Q3 us-gaap Common Stock Value
CommonStockValue
4000
CY2021Q4 us-gaap Common Stock Value
CommonStockValue
3000
CY2022Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
526099000
CY2021Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
377403000
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-356393000
CY2021Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-257159000
CY2022Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-413000
CY2021Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-35000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
169297000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
120212000
CY2022Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
364347000
CY2021Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
294651000
CY2022Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
18780000
CY2021Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
5000000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
49156000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
16000000
CY2022Q3 mirm Cost Of Sales1
CostOfSales1
2932000
CY2021Q3 mirm Cost Of Sales1
CostOfSales1
0
mirm Cost Of Sales1
CostOfSales1
7880000
mirm Cost Of Sales1
CostOfSales1
0
CY2022Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
26217000
CY2021Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
30471000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
75737000
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
103653000
CY2022Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
22513000
CY2021Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
17353000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
62598000
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
40185000
CY2022Q3 us-gaap Operating Expenses
OperatingExpenses
51662000
CY2021Q3 us-gaap Operating Expenses
OperatingExpenses
47824000
us-gaap Operating Expenses
OperatingExpenses
146215000
us-gaap Operating Expenses
OperatingExpenses
143838000
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-32882000
CY2021Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-42824000
us-gaap Operating Income Loss
OperatingIncomeLoss
-97059000
us-gaap Operating Income Loss
OperatingIncomeLoss
-127838000
CY2022Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
1352000
CY2021Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
72000
us-gaap Investment Income Interest
InvestmentIncomeInterest
1714000
us-gaap Investment Income Interest
InvestmentIncomeInterest
301000
CY2022Q3 mirm Other Nonoperating Interest Expense
OtherNonoperatingInterestExpense
3971000
CY2021Q3 mirm Other Nonoperating Interest Expense
OtherNonoperatingInterestExpense
5667000
mirm Other Nonoperating Interest Expense
OtherNonoperatingInterestExpense
11620000
mirm Other Nonoperating Interest Expense
OtherNonoperatingInterestExpense
13824000
CY2022Q3 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Issues
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues
0
CY2021Q3 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Issues
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues
-1355000
us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Issues
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues
-232000
us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Issues
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues
-417000
CY2022Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-192000
CY2021Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-35000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
953000
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-565000
CY2022Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-35693000
CY2021Q3 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-47099000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-105780000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-141509000
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
13000
CY2021Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
9000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
-6546000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
25000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-35706000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-47108000
us-gaap Net Income Loss
NetIncomeLoss
-99234000
us-gaap Net Income Loss
NetIncomeLoss
-141534000
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.02
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.02
CY2021Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.55
CY2021Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.55
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.03
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.03
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-4.68
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-4.68
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
34927790
CY2021Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30367727
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32809365
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
30250127
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
34927790
CY2021Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
30367727
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
32825314
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
30250127
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-35706000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-47108000
us-gaap Net Income Loss
NetIncomeLoss
-99234000
us-gaap Net Income Loss
NetIncomeLoss
-141534000
CY2022Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-191000
CY2021Q3 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
7000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-305000
us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-83000
CY2022Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-20000
CY2021Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
0
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-73000
us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-6000
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-35917000
CY2021Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-47101000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-99612000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-141623000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
120212000
CY2022Q1 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1477000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6561000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-36606000
CY2022Q1 us-gaap Other Comprehensive Income Loss Before Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
-96000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
108932000
CY2022Q2 us-gaap Stock Issued During Period Value Acquisitions
StockIssuedDuringPeriodValueAcquisitions
15585000
CY2022Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1408000
CY2022Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6818000
CY2022Q2 us-gaap Net Income Loss
NetIncomeLoss
-26922000
CY2022Q2 us-gaap Other Comprehensive Income Loss Before Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
-71000
CY2022Q2 us-gaap Stockholders Equity
StockholdersEquity
110687000
CY2022Q3 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
1378000
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7071000
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-35706000
CY2022Q3 us-gaap Other Comprehensive Income Loss Before Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
-211000
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
169297000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
172095000
CY2021Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
80000
CY2021Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
7038000
CY2021Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
5285000
CY2021Q1 us-gaap Net Income Loss
NetIncomeLoss
-50532000
CY2021Q1 us-gaap Other Comprehensive Income Loss Before Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
-83000
CY2021Q1 us-gaap Stockholders Equity
StockholdersEquity
133883000
CY2021Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
295000
CY2021Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4823000
CY2021Q2 us-gaap Net Income Loss
NetIncomeLoss
-43894000
CY2021Q2 us-gaap Other Comprehensive Income Loss Before Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
-13000
CY2021Q2 us-gaap Stockholders Equity
StockholdersEquity
95737000
CY2021Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
345000
CY2021Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
7415000
CY2021Q3 us-gaap Net Income Loss
NetIncomeLoss
-47108000
CY2021Q3 us-gaap Other Comprehensive Income Loss Before Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
7000
CY2021Q3 us-gaap Stockholders Equity
StockholdersEquity
56396000
us-gaap Profit Loss
ProfitLoss
-99234000
us-gaap Profit Loss
ProfitLoss
-141534000
us-gaap Share Based Compensation
ShareBasedCompensation
20111000
us-gaap Share Based Compensation
ShareBasedCompensation
17523000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
2037000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
253000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
315000
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
285000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
686000
us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
80000
mirm Non Cash Interest Expense On Revenue Interest Purchase Agreement
NonCashInterestExpenseOnRevenueInterestPurchaseAgreement
11620000
mirm Non Cash Interest Expense On Revenue Interest Purchase Agreement
NonCashInterestExpenseOnRevenueInterestPurchaseAgreement
13824000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Purchases Sales Issuances Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements
232000
us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Purchases Sales Issuances Settlements
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchasesSalesIssuancesSettlements
417000
mirm Change In Fair Value Of Contingent Liabilities Associated With Acquisition
ChangeInFairValueOfContingentLiabilitiesAssociatedWithAcquisition
1125000
mirm Change In Fair Value Of Contingent Liabilities Associated With Acquisition
ChangeInFairValueOfContingentLiabilitiesAssociatedWithAcquisition
0
mirm Tax Benefit Associated With An Acquisition
TaxBenefitAssociatedWithAnAcquisition
6580000
mirm Tax Benefit Associated With An Acquisition
TaxBenefitAssociatedWithAnAcquisition
0
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
13070000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
0
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1658000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2241000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
4046000
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
0
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
434000
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
374000
mirm Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities
IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities
7644000
mirm Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities
IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities
13635000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-528000
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-485000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-85866000
mirm Accrued Milestone Payments Classified As Intangible Assets Net
AccruedMilestonePaymentsClassifiedAsIntangibleAssetsNet
19000000
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2018-05-02
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2022Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-356400000
CY2022Q3 mirm Cash Cash Equivalents And Short And Long Term Investments
CashCashEquivalentsAndShortAndLongTermInvestments
285300000
CY2022Q3 mirm Cash Unrestricted Cash Equivalents And Short And Long Term Investments
CashUnrestrictedCashEquivalentsAndShortAndLongTermInvestments
185300000
us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;">Use of Estimates</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;font-style:italic;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">The preparation of consolidated financial statements in accordance with GAAP requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the financial statements and accompanying notes. These estimates and assumptions are based upon historical experience, knowledge of current events and various other factors believed to be reasonable under the circumstances, the results of which form the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results could differ materially from those estimates.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">In December 2019, a novel strain of coronavirus, which causes COVID-19, was identified. Due to the rapid and global spread of the virus, on March 11, 2020, the World Health Organization declared the COVID-19 outbreak a pandemic. To slow the proliferation of COVID-19, governments have implemented extraordinary measures, which include the mandatory closure of businesses, restrictions on travel and gatherings, and quarantine and physical distancing requirements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">There were no significant estimates contained in the preparation of the Company’s unaudited condensed consolidated financial statements or impacts to the Company’s unaudited condensed consolidated financial statements that were directly a result of the COVID-19 pandemic or the ongoing Ukraine-Russia conflict. The Company is not aware of any specific event or circumstance that would require an update to its estimates, judgments and assumptions or a revision of the carrying value of the Company’s assets or liabilities</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:&quot;Times New Roman&quot;, serif;min-width:fit-content;">.</span></p>
CY2022Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
35759000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
31340000
CY2022Q3 us-gaap Restricted Cash Equivalents
RestrictedCashEquivalents
100000000
CY2021Q4 us-gaap Restricted Cash Equivalents
RestrictedCashEquivalents
100000000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
135759000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
131340000
CY2022Q3 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
47107000
CY2022Q3 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
2075000
CY2022Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
45032000
CY2021Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
19000000
CY2021Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
260000
CY2021Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
18740000
CY2022Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1000000.0
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
1800000
CY2021Q3 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0
us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
0
CY2022Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Next Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
1042000
CY2022Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Two
FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
4165000
CY2022Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Three
FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
4165000
CY2022Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Four
FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
4165000
CY2022Q3 us-gaap Finite Lived Intangible Assets Amortization Expense Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
4165000
CY2022Q3 us-gaap Finite Lived Intangible Assets Amortization Expense After Year Five
FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive
27330000
CY2022Q3 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
45032000
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-35706000
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-99234000
CY2022Q3 mirm Fair Value Adjustment Of Holdback Indemnification Liability
FairValueAdjustmentOfHoldbackIndemnificationLiability
0
mirm Fair Value Adjustment Of Holdback Indemnification Liability
FairValueAdjustmentOfHoldbackIndemnificationLiability
149000
CY2022Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-35706000
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-99383000
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
34927790
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
32809365
CY2022Q3 mirm Weighted Average Holdback Indemnification Shares Issuable
WeightedAverageHoldbackIndemnificationSharesIssuable
0
mirm Weighted Average Holdback Indemnification Shares Issuable
WeightedAverageHoldbackIndemnificationSharesIssuable
15949
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
34927790
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
32825314
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.02
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.03
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.02
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.03
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
32494
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
9179399
CY2021 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
7086146
CY2022Q1 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Issues
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues
0
CY2022Q2 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Issues
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues
-232000
CY2022Q3 us-gaap Fair Value Net Derivative Asset Liability Measured On Recurring Basis Unobservable Inputs Reconciliation Issues
FairValueNetDerivativeAssetLiabilityMeasuredOnRecurringBasisUnobservableInputsReconciliationIssues
0
CY2022Q3 mirm Cash Equivalents And Available For Sale Debt Securities Amortized Cost Basis
CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis
280987000
CY2022Q3 mirm Cash Equivalents And Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
341000
CY2022Q3 mirm Cash Equivalents And Available For Sale Securities Debt Securities
CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities
280646000
CY2022Q3 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
31058000
CY2022Q3 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
100000000
CY2022Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
149588000
CY2022Q3 mirm Cash Equivalents And Available For Sale Securities Debt Securities
CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities
280646000
CY2021Q4 mirm Cash Equivalents And Available For Sale Debt Securities Amortized Cost Basis
CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis
258640000
CY2021Q4 mirm Cash Equivalents And Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
36000
CY2021Q4 mirm Cash Equivalents And Available For Sale Securities Debt Securities
CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities
258604000
CY2021Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
28420000
CY2021Q4 us-gaap Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
100000000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
125201000
CY2021Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
4983000
CY2021Q4 mirm Cash Equivalents And Available For Sale Securities Debt Securities
CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities
258604000
CY2022Q3 us-gaap Available For Sale Securities Debt Maturities Next Rolling Twelve Months Fair Value
AvailableForSaleSecuritiesDebtMaturitiesNextRollingTwelveMonthsFairValue
149588000
CY2022Q3 mirm Held To Maturity Securities Debt Maturities Rolling Year One Through Two Fair Value
HeldToMaturitySecuritiesDebtMaturitiesRollingYearOneThroughTwoFairValue
0
CY2022Q3 us-gaap Held To Maturity Securities Fair Value
HeldToMaturitySecuritiesFairValue
149588000
CY2022Q3 mirm Available For Sale Securities Gross Realized Gain Loss Net1
AvailableForSaleSecuritiesGrossRealizedGainLossNet1
0
CY2021Q3 mirm Available For Sale Securities Gross Realized Gain Loss Net1
AvailableForSaleSecuritiesGrossRealizedGainLossNet1
0
mirm Available For Sale Securities Gross Realized Gain Loss Net1
AvailableForSaleSecuritiesGrossRealizedGainLossNet1
0
mirm Available For Sale Securities Gross Realized Gain Loss Net1
AvailableForSaleSecuritiesGrossRealizedGainLossNet1
0
CY2021Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
0
CY2022Q3 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
0
us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
0
us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
0
CY2022Q3 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
0
CY2021Q4 us-gaap Inventory Raw Materials And Supplies
InventoryRawMaterialsAndSupplies
856000
CY2022Q3 us-gaap Inventory Work In Process
InventoryWorkInProcess
6764000
CY2021Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
570000
CY2022Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
179000
CY2021Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
87000
CY2022Q3 us-gaap Inventory Net
InventoryNet
6943000
CY2021Q4 us-gaap Inventory Net
InventoryNet
1513000
CY2022Q3 mirm Accrued Clinical Trials Current
AccruedClinicalTrialsCurrent
9839000
CY2021Q4 mirm Accrued Clinical Trials Current
AccruedClinicalTrialsCurrent
6732000
CY2022Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
5776000
CY2021Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2458000
CY2022Q3 mirm Accrued Contract Manufacturing And Non Clinical Costs Current
AccruedContractManufacturingAndNonClinicalCostsCurrent
5722000
CY2021Q4 mirm Accrued Contract Manufacturing And Non Clinical Costs Current
AccruedContractManufacturingAndNonClinicalCostsCurrent
4635000
CY2022Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
10158000
CY2021Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
9988000
CY2022Q3 mirm Accrued Rebates Payable Current
AccruedRebatesPayableCurrent
5171000
CY2021Q4 mirm Accrued Rebates Payable Current
AccruedRebatesPayableCurrent
265000
CY2022Q3 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
1645000
CY2021Q4 us-gaap Accrued Royalties Current
AccruedRoyaltiesCurrent
345000
CY2022Q3 mirm Accrued Collaboration Liabilities Current
AccruedCollaborationLiabilitiesCurrent
0
CY2021Q4 mirm Accrued Collaboration Liabilities Current
AccruedCollaborationLiabilitiesCurrent
6300000
CY2022Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
38311000
CY2021Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
30723000
CY2021Q4 mirm Revenue Interest Liability
RevenueInterestLiability
129923000
CY2022Q1 mirm Interest Expense Accrued
InterestExpenseAccrued
3774000
CY2022Q1 mirm Revenue Interest Payments
RevenueInterestPayments
-757000
CY2022Q1 mirm Revenue Interest Liability
RevenueInterestLiability
132940000
CY2022Q2 mirm Interest Expense Accrued
InterestExpenseAccrued
3875000
CY2022Q2 mirm Revenue Interest Payments
RevenueInterestPayments
-1099000
CY2022Q2 mirm Revenue Interest Liability
RevenueInterestLiability
135716000
CY2022Q3 mirm Interest Expense Accrued
InterestExpenseAccrued
3971000
CY2022Q3 mirm Revenue Interest Payments
RevenueInterestPayments
-1670000
CY2022Q3 mirm Revenue Interest Liability
RevenueInterestLiability
138017000
CY2022Q2 us-gaap Payments To Acquire Businesses Gross
PaymentsToAcquireBusinessesGross
2600000
CY2019Q1 us-gaap Area Of Land
AreaOfLand
5600
us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
The lease term is approximately four years with an option to extend the term for one five-year term, which at the time was not reasonably assured of exercise and therefore, not included in the lease term.
CY2019Q1 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P4Y
CY2019Q1 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
CY2019Q1 mirm Tenant Improvement Allowance
TenantImprovementAllowance
400000
CY2022Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.080
CY2022Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1300000
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
2100000
CY2022Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y4M24D
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
225000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
916000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
925000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
229000
CY2022Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
2295000
CY2022Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
209000
CY2022Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
2086000
CY2022Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
200000
CY2021Q3 us-gaap Operating Lease Expense
OperatingLeaseExpense
200000
us-gaap Operating Lease Expense
OperatingLeaseExpense
500000
us-gaap Operating Lease Expense
OperatingLeaseExpense
500000
CY2020Q3 mirm Maximum Amount Of Sale Covered In Shelf Registration Statement
MaximumAmountOfSaleCoveredInShelfRegistrationStatement
300000000.0
CY2022Q3 mirm Common Stock Aggregate Offering Price Remaining
CommonStockAggregateOfferingPriceRemaining
46300000
CY2022Q3 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
12000369
CY2021Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
10286323
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6908000
CY2021Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
7415000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
20111000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
17523000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-99611000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
132322000
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
179055000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
113300000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
117600000
mirm Proceeds From Paydowns Of Investments
ProceedsFromPaydownsOfInvestments
0
mirm Proceeds From Paydowns Of Investments
ProceedsFromPaydownsOfInvestments
2000000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
36000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
21000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-19058000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-59476000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
21289000
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
86358000
us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
6914000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
5295000
us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
1363000
mirm Proceeds From Revenue Interest Liability
ProceedsFromRevenueInterestLiability
0
mirm Proceeds From Revenue Interest Liability
ProceedsFromRevenueInterestLiability
64574000
mirm Repayment Of Revenue Interest
RepaymentOfRevenueInterest
-3526000
mirm Repayment Of Revenue Interest
RepaymentOfRevenueInterest
0
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
109416000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
72851000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-73000
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-6000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
4419000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-86242000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
131340000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
142086000
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
135759000
CY2021Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
55844000
us-gaap Operating Lease Payments
OperatingLeasePayments
661000
us-gaap Operating Lease Payments
OperatingLeasePayments
645000
mirm Inventory Purchases In Accrued Liabilities
InventoryPurchasesInAccruedLiabilities
1045000
mirm Inventory Purchases In Accrued Liabilities
InventoryPurchasesInAccruedLiabilities
0
mirm Stock Based Compensation Capitalized To Inventory
StockBasedCompensationCapitalizedToInventory
339000
mirm Stock Based Compensation Capitalized To Inventory
StockBasedCompensationCapitalizedToInventory
0
mirm Transaction Costs From Public Offering In Accrued Liabilities
TransactionCostsFromPublicOfferingInAccruedLiabilities
281000
mirm Transaction Costs From Public Offering In Accrued Liabilities
TransactionCostsFromPublicOfferingInAccruedLiabilities
0
mirm Issuance Of Common Stock In Exchange For Acquired Intangible Assets
IssuanceOfCommonStockInExchangeForAcquiredIntangibleAssets
15585000
mirm Issuance Of Common Stock In Exchange For Acquired Intangible Assets
IssuanceOfCommonStockInExchangeForAcquiredIntangibleAssets
0
mirm Indemnification Holdback Liability In Exchange For Acquired Intangible Assets
IndemnificationHoldbackLiabilityInExchangeForAcquiredIntangibleAssets
831000
mirm Indemnification Holdback Liability In Exchange For Acquired Intangible Assets
IndemnificationHoldbackLiabilityInExchangeForAcquiredIntangibleAssets
0
mirm Contingent Milestone Liability For Common Stock Issuance For Acquired Intangible Assets
ContingentMilestoneLiabilityForCommonStockIssuanceForAcquiredIntangibleAssets
4600000
mirm Contingent Milestone Liability For Common Stock Issuance For Acquired Intangible Assets
ContingentMilestoneLiabilityForCommonStockIssuanceForAcquiredIntangibleAssets
0
mirm Deferred Tax Liability Incurred From Acquired Intangible
DeferredTaxLiabilityIncurredFromAcquiredIntangible
6580000
mirm Deferred Tax Liability Incurred From Acquired Intangible
DeferredTaxLiabilityIncurredFromAcquiredIntangible
0
mirm Accrued Milestone Payments Classified As Intangible Assets Net
AccruedMilestonePaymentsClassifiedAsIntangibleAssetsNet
0

Files In Submission

Name View Source Status
0000950170-22-023519-index-headers.html Edgar Link pending
0000950170-22-023519-index.html Edgar Link pending
0000950170-22-023519.txt Edgar Link pending
0000950170-22-023519-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
mirm-20220930.htm Edgar Link pending
mirm-20220930.xsd Edgar Link pending
mirm-ex31_1.htm Edgar Link pending
mirm-ex31_2.htm Edgar Link pending
mirm-ex32_1.htm Edgar Link pending
mirm-ex32_2.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
mirm-20220930_pre.xml Edgar Link unprocessable
mirm-20220930_lab.xml Edgar Link unprocessable
mirm-20220930_cal.xml Edgar Link unprocessable
mirm-20220930_htm.xml Edgar Link completed
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
mirm-20220930_def.xml Edgar Link unprocessable